NCT04774718: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors

NCT04774718
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ALK
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: up to 17 Years (Child)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with prior use of ALK inhibitors
https://ClinicalTrials.gov/show/NCT04774718

Comments are closed.

Up ↑